CEL Stock Overview
Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Celadon Pharmaceuticals Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.05 |
| 52 Week High | UK£1.80 |
| 52 Week Low | UK£0.73 |
| Beta | 0.043 |
| 1 Month Change | 27.27% |
| 3 Month Change | 23.53% |
| 1 Year Change | -27.59% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -27.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| CEL | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -10.6% | 8.3% | 2.2% |
| 1Y | -27.6% | 4.9% | 0.9% |
Return vs Industry: CEL underperformed the UK Pharmaceuticals industry which returned 0.2% over the past year.
Return vs Market: CEL underperformed the UK Market which returned 0.6% over the past year.
Price Volatility
| CEL volatility | |
|---|---|
| CEL Average Weekly Movement | 10.8% |
| Pharmaceuticals Industry Average Movement | 9.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: CEL has not had significant price volatility in the past 3 months.
Volatility Over Time: CEL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 24 | Jim Short | celadonpharma.com/ |
Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.
Celadon Pharmaceuticals Plc Fundamentals Summary
| CEL fundamental statistics | |
|---|---|
| Market cap | UK£67.42m |
| Earnings (TTM) | -UK£7.96m |
| Revenue (TTM) | UK£21.00k |
3,210x
P/S Ratio-8.5x
P/E RatioIs CEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CEL income statement (TTM) | |
|---|---|
| Revenue | UK£21.00k |
| Cost of Revenue | UK£101.00k |
| Gross Profit | -UK£80.00k |
| Other Expenses | UK£7.88m |
| Earnings | -UK£7.96m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | -380.95% |
| Net Profit Margin | -37,904.76% |
| Debt/Equity Ratio | 1.0% |
How did CEL perform over the long term?
See historical performance and comparison